{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS&page=6", "query": { "condition": "SOLID TUMORS", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 5449, "total_pages": 545, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SOLID+TUMORS&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T16:56:42.916Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03735095", "title": "Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Lung Carcinoma", "Non-Small Cell Lung Carcinoma", "Small Cell Lung Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Solid Tumor" ], "interventions": [ { "name": "Porfimer Sodium", "type": "DRUG" }, { "name": "Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2020-02-12", "completion_date": "2024-07-26", "has_results": true, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-14T16:56:42.916Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03735095" }, { "nct_id": "NCT01806675", "title": "18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Male Breast Cancer", "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Brain Tumor", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Hypopharyngeal Cancer", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Laryngeal Cancer", "Recurrent Lip and Oral Cavity Cancer", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Nasopharyngeal Cancer", "Recurrent Non-small Cell Lung Cancer", "Recurrent Oropharyngeal Cancer", "Recurrent Pancreatic Cancer", "Recurrent Paranasal Sinus and Nasal Cavity Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Pancreatic Cancer", "Stage IV Renal Cell Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVB Colon Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVC Salivary Gland Cancer", "Tongue Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "18F-fludeoxyglucose (18F-FDG)", "type": "DRUG" }, { "name": "18F-FPPRGD2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanjiv Sam Gambhir", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2013-03-04", "completion_date": "2019-04", "has_results": true, "last_update_posted_date": "2019-10-03", "last_synced_at": "2026-10-14T16:56:42.916Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01806675" }, { "nct_id": "NCT00996957", "title": "Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Multiple Myeloma" ], "interventions": [ { "name": "ACE-041", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2009-10", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2013-03-18", "last_synced_at": "2026-10-14T16:56:42.916Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Durham, North Carolina • Nashville, Tennessee + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00996957" }, { "nct_id": "NCT00349167", "title": "PR-104 in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "PR-104", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Proacta, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2005-12", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2012-11-30", "last_synced_at": "2026-10-14T16:56:42.916Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00349167" }, { "nct_id": "NCT05377528", "title": "Study of AGEN1571 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "AGEN1571", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Botensilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-07-19", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-10-14T16:56:42.916Z", "location_count": 6, "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05377528" }, { "nct_id": "NCT03589339", "title": "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Radiotherapy", "Immunotherapy", "Microsatellite Instability-High Solid Malignant Tumour", "Metastasis From Malignant Tumor of Liver", "Squamous Cell Carcinoma of Head and Neck", "Metastasis From Malignant Tumor of Cervix", "Metastatic Renal Cell Carcinoma", "Metastasis From Malignant Melanoma of Skin (Disorder)", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic NSCLC", "Metastasis From Malignant Tumor of Bladder (Disorder)" ], "interventions": [ { "name": "NBTXR3", "type": "DRUG" }, { "name": "SABR", "type": "RADIATION" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Nanobiotix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2019-01-16", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-10-14T16:56:42.916Z", "location_count": 13, "location_summary": "San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03589339" }, { "nct_id": "NCT04417465", "title": "First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-CLS-579", "type": "DRUG" }, { "name": "PD-1 inhibitor", "type": "DRUG" }, { "name": "VEGFR TKI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2020-06-03", "completion_date": "2025-08-21", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-14T16:56:42.916Z", "location_count": 5, "location_summary": "Springdale, Arkansas • New Haven, Connecticut • Fort Wayne, Indiana + 2 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04417465" }, { "nct_id": "NCT00920257", "title": "A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK2141795", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2009-06-16", "completion_date": "2013-04-17", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-14T16:56:42.916Z", "location_count": 6, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00920257" }, { "nct_id": "NCT05988892", "title": "A Study of Physical Activity in Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Hematopoietic and Lymphatic System Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Physical Activity", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-06-29", "completion_date": "2025-04-23", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-14T16:56:42.916Z", "location_count": 4, "location_summary": "Albert Lea, Minnesota • Mankato, Minnesota • Eau Claire, Wisconsin + 1 more", "locations": [ { "city": "Albert Lea", "state": "Minnesota" }, { "city": "Mankato", "state": "Minnesota" }, { "city": "Eau Claire", "state": "Wisconsin" }, { "city": "La Crosse", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05988892" }, { "nct_id": "NCT00068445", "title": "Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurotoxicity", "Pain", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "lamotrigine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2004-02", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2018-05-04", "last_synced_at": "2026-10-14T16:56:42.916Z", "location_count": 23, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068445" } ] }